




PCT / SE 2004 / 0 0 0 9 6 9



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subject the company to certain additional company law rules.



Signed *[Signature]*

Dated 5 May 2004

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Patents Form 1/77


Patents Act 1977
(Rule 1)



18JUN03 0815757-7 002934
01/17705 0.00-031/057 7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 101084-1 GB

2. Patent application number
(The Patent Office will fill in this part)

0314059.7

18 JUN 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
SE-151 85 Sodertalje
Sweden

Patents ADP number (if you know it)

7822448003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

THERAPEUTIC AGENTS

5. Name of your agent (if you have one)

Thomas Kerr MILLER

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield,
Cheshire SK10 4TG

Patents ADP number (if you know it)

7822471002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 20

Claim(s) 4

Abstract 1

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

17/06/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTSField of invention


5 The present invention relates to certain pyrazine compounds of formula I, to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

10 Background of the invention

It is known that certain CB₁ modulators (known as antagonists or inverse agonists) are useful in the treatment of obesity, psychiatric and neurological disorders (WO01/70700 and EP 656354). However, there is a need for CB₁ modulators with improved
 15 physicochemical properties and/or DMPK properties and/or pharmacodynamic properties.

Pyrazinecarboxamides are reported to possess antithrombotic properties (WO 92/ 02513). The compounds disclosed in this document are disclaimed from the compound claims of the present invention. 5,6-Diphenyl-2-pyrazinecarboxylic acid is disclosed in CH 458 361.
 20

Co-pending application PCT/GB02/05742 discloses compounds of the general formula (A).



25 and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which

R¹ and R² independently represent :

a C₁₋₆alkyl group;

an (amino) C_{1-4} alkyl- group in which the amino is optionally substituted by one or more C_{1-3} alkyl groups;

an optionally substituted non-aromatic C_{3-15} carbocyclic group;

a (C_{3-12} cycloalkyl) C_{1-3} alkyl- group;

5 a group $-(CH_2)_r(phenyl)_s$ in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by one, two or three groups represented by Z;

naphthyl;

anthracenyl;

10 a saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following : oxygen, sulphur or an additional nitrogen wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy or benzyl ;
1-adamantylmethyl;

a group $-(CH_2)_t Het$ in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally
15 substituted by one or more C_{1-3} alkyl groups and Het represents an aromatic heterocycle optionally substituted by one, two or three groups selected from a C_{1-5} alkyl group, a C_{1-5} alkoxy group or halo;

or R^1 represents H and R^2 is as defined above;

or R^1 and R^2 together with the nitrogen atom to which they are attached represent a

20 saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following : oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy or benzyl ;

X is CO or SO_2 ;

Y is absent or represents NH optionally substituted by a C_{1-3} alkyl group;

25 R^3 and R^4 independently represent phenyl, thienyl or pyridyl each of which is optionally substituted by one, two or three groups represented by Z;

Z represents a C_{1-3} alkyl group, a C_{1-3} alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di


C₁₋₃alkylamino, mono or di C₁₋₃alkylamido, C₁₋₃alkylsulphonyl, C₁₋₃alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C₁₋₃alkyl carbamoyl, sulphamoyl and acetyl; and

R⁵ is H, a C₁₋₃alkyl group, a C₁₋₃alkoxymethyl group, trifluoromethyl, a hydroxyC₁₋₃alkyl group, C₁₋₃alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C₁₋₃alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula -CONHN^aR^b wherein R^a and R^b are as previously defined for R¹ and R² respectively;

with the proviso that when R¹ and R² together with the nitrogen atom to which they are attached represent 4-methylpiperazin-1-yl or R¹ represents H and R² represents methyl or 1-benzylpiperidin-4-yl; X is CO; Y is absent and R⁵ is H; then R³ and R⁴ do not both represent 4-methoxyphenyl; and their use in the treatment of obesity, psychiatric and neurological disorders.

15 Description of the invention

The invention relates to a compound of formula (I)



wherein R¹ and R² independently represent phenyl, thienyl or pyridyl each of which is independently optionally substituted by one or more groups represented by Z;

Z represents a C₁₋₈alkyl group, a C₁₋₆alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, mono or di C₁₋₃alkylamido, C₁₋₃alkylsulphonyl, C₁₋₃alkylsulphonyloxy, C₁₋₃alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C₁₋₃alkyl carbamoyl, sulphamoyl, acetyl, an aromatic heterocyclic group, optionally substituted by halo, alkyl, trifluoromethyl or trifluoromethoxy and a saturated or partially unsaturated 5 to 8 membered heterocyclic

group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, hydroxy, fluoro, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl ;

5

R^3 represents a group of formula $(CH_2)_nCOOR^7$

in which n is 0, 1, 2, 3 or 4 and

R^7 represents a C_{4-12} alkyl group, a C_{3-12} cycloalkyl group or a $(C_{3-12}$ cycloalkyl) C_{1-3} alkyl-group each of which is optionally substituted by one or more of the following: a C_{1-6} alkyl group; fluoro, amino or hydroxy, or

10

R^7 represents a group $-(CH_2)_a$ phenyl in which a is 0, 1, 2, 3 or 4 and the phenyl group is optionally substituted by one or more groups represented by Z which may be the same or different or

15

R^7 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of the of the following : oxygen, sulphur or nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, C_{1-3} acyl groups, hydroxy, amino or benzyl; or

20

R^3 represents a group of formula $-(CH_2)_o-O-(CH_2)_p-R^8$ in which o and p independently represent an integer 0, 1, 2, 3 or 4 and R^8 represents a C_{1-12} alkyl group optionally substituted by one or more of the following: a C_{1-6} alkyl group; fluoro, hydroxy, or or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl ;

25

or R^8 represents phenyl optionally independently substituted by one or more Z groups or R^8 represents an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one following : oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different ;

30

R^3 represents a group of formula $-(CH_2)_qR^9$ in which q is 0, 1, 2, 3 or 4 and R^9 represents a C_{3-12} cycloalkyl group, phenyl, an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one
 5 following : oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different ;
 or

R^4 represents a group of formula $-(CH_2)_m-O-(CO)-R^{10}$ in which m represents an integer
 10 0, 1, 2, 3 or 4 , and in which R^{10} represents a C_{1-12} alkyl group optionally substituted by one or more fluoro, hydroxy, or amino or R^{10} represents a group of formula $-(CH_2)_qR^9$ in which q and R^9 are as previously described.

It will be understood that where a substituent Z is present in more than one group that these
 15 substituents are independently selected and may be the same or different.

The term aromatic heterocyclic group means an aromatic 5-, 6-, or 7-membered monocyclic ring or a 9- or 10-membered bicyclic ring, with up to five ring heteroatoms selected from oxygen, nitrogen and sulfur. Suitable aromatic heterocyclic groups include,
 20 for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl. Preferably furyl, pyrrolyl,
 25 thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxazolyl thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazenyl and more preferably pyrrolyl, thienyl, imidazolyl, oxazolyl or pyridyl.

Suitable saturated or partially unsaturated 5 to 8 membered heterocyclic group containing
 30 one or more heteroatoms selected from nitrogen, oxygen or sulphur include, for example

oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2,3-dihydro-1,3-thiazolyl, 1,3-thiazolidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, 1-oxotetrahydrothienyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, more preferably tetrahydrofuran-3-yl, tetrahydropyran-4-yl, pyrrolidin-3-yl, morpholino, piperidino, piperidin-4-yl or piperazin-1-yl.

Further values of R^1 , R^2 and R^3 in compounds of formula I now follow. It will be understood that such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

Particularly R^1 and R^2 each represent phenyl independently optionally substituted by one or more chloro.

Particularly R^3 represents C_{4-12} alkoxycarbonyl.

Particularly R^3 represents a benzyloxymethyl group optionally substituted by Z in the phenyl ring of the benzyl group.

Particularly R^3 represents a group $C(O)O$ -Het wherein Het is piperino, morpholino or pyrrolidino.

"Pharmaceutically acceptable salts", where such salts are possible, include pharmaceutically acceptable acid and base addition salts. All tautomers, where possible, are included within the scope of the invention.

Specific compounds of the invention are one or more of the following:

2,3-bis(4-chlorophenyl)-5-{[(4-fluorobenzyl)oxy]methyl} pyrazine
 2,3-BIS(4-CHLOROPHENYL)-5-[(PIPERIDINE-1-YLOXY)CARBONYL]PYRAZINE

and pharmaceutically acceptable salts thereof.

Methods of preparation

The compounds of the invention may be prepared as described in the Examples.

Pharmaceutical preparations

5 The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable addition
10 salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.

15 Suitable daily doses of the compounds of the invention in the therapeutic treatment of humans are about 0.001-10 mg/kg body weight, preferably 0.01-1 mg/kg body weight.

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.5mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25mg, 50mg, 100mg
20 and 250mg.

According to a further aspect of the invention there is also provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants,
25 diluents and/or carriers.

Pharmacological properties

30 The compounds of formula (I) are useful for the treatment of obesity, psychiatric disorders such as psychotic disorders, schizophrenia, bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and related

conditions, and neurological disorders such as dementia, neurological disorders(e.g. Multiple Sclerosis), Raynaud's syndrome, Parkinson's disease, Huntington's chorea and Alzheimer's disease. The compounds are also potentially useful for the treatment of immune, cardiovascular, reproductive and endocrine disorders, septic shock and diseases
5 related to the respiratory and gastrointestinal systems (e.g. diarrhea). The compounds are also potentially useful as agents in treatment of extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates, etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms. The compounds may also eliminate the increase in weight which normally accompanies the
10 cessation of smoking.

In another aspect the present invention provides a compound of formula I as previously defined for use as a medicament.

15 In a further aspect the present invention provides the use of a compound of formula I in the preparation of a medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as psychotic disorders, schizophrenia, bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and
20 related conditions, neurological disorders such as dementia, neurological disorders (e.g. Multiple Sclerosis), Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems (e.g. diarrhea), and extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates,
25 etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms.

In a still further aspect the present invention provides a method of treating obesity, psychiatric disorders such as psychotic disorders such as schizophrenia and bipolar
30 disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and related conditions, neurological disorders such as dementia,

neurological disorders (e.g. Multiple Sclerosis), Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems (e.g. diarrhea), and extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates, etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms comprising administering a pharmacologically effective amount of a compound of formula I to a patient in need thereof.

The compounds of the present invention are particularly suitable for the treatment of obesity, e.g. by reduction of appetite and body weight, maintenance of weight reduction and prevention of rebound.

Combination Therapy

The compounds of the invention may be combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of obesity such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and atherosclerosis. For example, a compound of the present invention may be used in combination with a compound that affects thermogenesis, lipolysis, fat absorption, satiety, or gut motility. The compounds of the invention may be combined with another therapeutic agent that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

The compounds of the invention may be used alongside other therapies for the treatment of obesity and its associated complications the metabolic syndrome and type 2 diabetes, these include biguanide drugs, insulin (synthetic insulin analogues) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors).

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt thereof may be administered in association with a PPAR modulating agent. PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma

agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art.

- 5 In addition the combination of the invention may be used in conjunction with a sulfonylurea. The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase
10 inhibitor is a statin

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.

15

The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor). The present invention also includes a compound of the present invention in combination with a bile acid binding resin.

- 20 The present invention also includes a compound of the present invention in combination with a bile acid sequestering agent, for example colestipol or cholestyramine or cholestagel

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, optionally
25 together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

- a CETP (cholesteryl ester transfer protein) inhibitor;
- a cholesterol absorption antagonist;
- a MTP (microsomal transfer protein) inhibitor ;
- 30 a nicotinic acid derivative, including slow release and combination products;
- a phytosterol compound ;
- probucol;

an anti-coagulant;
an omega-3 fatty acid ;
another anti-obesity compound;
an antihypertensive compound for example an angiotensin converting enzyme (ACE)
5 inhibitor, an angiotensin II receptor antagonist, an andrenergic blocker, an alpha
andrenergic blocker, a beta andrenergic blocker, a mixed alpha/beta andrenergic blocker,
an andrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic
or a vasodilator;
a Melanin concentrating hormone (MCH) antagonist;
10 a PDK inhibitor; or
modulators of nuclear receptors for example LXR, FXR, RXR, and RORalpha;
an SSRI;
a serotonin antagonist;
or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof,
15 optionally together with a pharmaceutically acceptable diluent or carrier to a warm-
blooded animal, such as man in need of such therapeutic treatment.

Therefore in an additional feature of the invention, there is provided a method for for the
treatment of obesity and its associated complications in a warm-blooded animal, such as
20 man, in need of such treatment which comprises administering to said animal an effective
amount of a compound of formula I, or a pharmaceutically acceptable salt thereof in
simultaneous, sequential or separate administration with an effective amount of a
compound from one of the other classes of compounds described in this combination
section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug
25 thereof.

Therefore in an additional feature of the invention, there is provided a method of treating
hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such
treatment which comprises administering to said animal an effective amount of a
30 compound of formula I, or a pharmaceutically acceptable salt thereof in simultaneous,
sequential or separate administration with an effective amount of a compound from one of

the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

According to a further aspect of the invention there is provided a pharmaceutical
5 composition which comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, and a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

10 According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15 According to a further aspect of the present invention there is provided a kit comprising:
a) a compound of formula I, or a pharmaceutically acceptable salt thereof, in a first unit dosage form;
b) a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug
20 thereof; in a second unit dosage form; and
c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:
a) a compound of formula I, or a pharmaceutically acceptable salt thereof, together with a
25 pharmaceutically acceptable diluent or carrier, in a first unit dosage form;
b) a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and
c) container means for containing said first and second dosage forms.

30

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and one of the other

compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the the treatment of obesity and its associated complications in a warm-blooded animal, such as man.

5

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

10

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

20

Furthermore, a compound of the invention may also be combined with therapeutic agents that are useful in the treatment of disorders or conditions associated with obesity (such as type II diabetes, metabolic syndrome, dyslipidemia, impaired glucose tolerance, hypertension, coronary heart disease, non-alcoholic steatorrheic hepatitis, osteoarthritis and some cancers) and psychiatric and neurological conditions.

25

Experimental

Abbreviations

30

DCM - dichloromethane

DMF - dimethylformamide

DMAP - 4-dimethylaminopyridine

EDC - 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

TEA - triethylamine

TFA - trifluoroacetic acid

DMSO-dimethyl sulfoxide

5 DEA - Diethylamine

PCC - Pyridinium chlorochromate

DCM - Dichloromethane

PyBOP - benzotriazol-1-yl-oxytri-pyrrolidinophosphonium hexafluorophosphate

HBTU - *O*-Benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium Hexafluorophosphate

10 DAST-(diethyl amino)sulphur trifluoride

DIEA - *N,N*-diisopropylethylamine

t triplet

s singlet

d doublet

15 q quartet

qvint quintet

m multiplet

br broad

bs broad singlet

20 dm doublet of multiplet

bt broad triplet

dd doublet of doublet

General Experimental Procedures

Mass spectra were recorded on either a Micromass ZQ single quadrupole or a Micromass
 25 LCZ single quadrupole mass spectrometer both equipped with a pneumatically assisted
 electrospray interface (LC-MS). ¹H NMR measurements were performed on either a
 Varian Mercury 300 or a Varian Inova 500, operating at ¹H frequencies of 300 and 500
 MHz respectively. Chemical shifts are given in ppm with CDCl₃ as internal standard.
 CDCl₃ is used as the solvent for NMR unless otherwise stated. Purification was performed
 30 on a semipreparative HPLC with a mass triggered fraction collector, Shimadzu QP 8000
 single quadrupole mass spectrometer equipped with 19 x 100 mm C8 column. The mobile

phase used was, if nothing else is stated, acetonitrile and buffer (0.1 M NH_4Ac :acetonitrile 95:5).


For isolation of isomers, a Kromasil CN E9344 (250 x 20 mm i.d.) column was used.

5 Heptane:ethyl acetate:DEA 95:5:0.1 was used as mobile phase (1 ml/min). Fraction collection was guided using a UV-detector (330 nm).

10

Preparation Of Starting Materials and Intermediates

Inte. A : 1,2-bis(4-chlorophenyl)-2-hydroxyethanone




15 To 4-chlorobenzaldehyde (140.6 g, 1 mol) in ethanol (130 ml) was added a solution of sodium cyanide (10.6 g, 0.216 mol) in water (105 ml). The mixture was heated at reflux for 2.5 h and then extracted with DCM. The organic phase was washed with sodium bisulfite solution and the solvent was evaporated in vacuo. The compound was isolated by crystallization from diethyl ether/heptan. 48 g, 34%.

20 ^1H NMR (400 MHz) δ 7.82 (d, 2H), 7.38 (d, 2H), 7.30 (d, 2H), 7.24 (d, 2H), 5.87 (s, 1H), 4.47 (s, 1H).

MS m/z 279, 281 (M-H) $^-$.


Inte. B: 1,2-bis(4-chlorophenyl)ethane-1,2-dione



1,2-bis(4-chlorophenyl)-2-hydroxyethanone, Inte. A (90 g, 0.320 mol) and nitric acid (170 ml) were heated at 100°C until the evolution of nitrogen oxides ceased after 4 hours. The reaction mixture was cooled, and water (250 ml) was carefully added. The crude product
5 was filtered, washed several times with water and dried under reduced pressure to give a yellow solid (40.4 g, 45%).

^1H NMR (500 MHz) δ 7.94 (d, 4H), 7.53 (d, 4H).

10 **Inte. C:** 5,6-Bis-(4-chlorophenyl) pyrazine-2-carboxylic acid




The monohydrochloride of 2,3-diaminopropionic acid (2.5 g, 17.78 mmol) and 1,2-bis(4-chlorophenyl)ethane-1,2-dione, **Inte. B** (4.965 g, 17.78 mmol), were dissolved in a
15 solution of sodium hydroxide (3.0 g, 75 mmol) in methanol (100 ml) and refluxed for 2 hours under argon. Air was bubbled through and the reaction continued at room temperature for 20 hours. The methanol was evaporated and the product redissolved in water. Hydrochloric acid (aq, 2 M) was added until the mixture reached pH 2. The solution was extracted with diethyl ether and dried over MgSO_4 . Recrystallisation from methanol
20 gave the title compound (1.57g, 26%).

^1H NMR (399.964 MHz) δ 9.41 (s, 1H), 7.48-7.32 (m, 8H).


MS m/z 343, 345, 347 (M-H)⁻.

Inte. D : 5,6-bis(4-chlorophenyl)pyrazine-2-carbonyl chloride



5 To a suspension of 5,6-bis(4-chlorophenyl)pyrazine-2-carboxylic acid, **Inte. C** (485 mg, 1.41 mmol) in DCM (5 ml) was added a solution of oxalyl chloride (1 ml, 7.88 mmol) in DCM (10 ml) and DMF (0.2 ml) at room temperature. The solvent and unreacted oxalyl chloride was evaporated. The crude product was used without further purification.

10 **Inte. E :** [5,6-bis(4-chlorophenyl)pyrazin-2-yl]methanol



15 To a suspension of 5,6-bis(4-chlorophenyl)pyrazine-2-carboxylic acid, **Inte. C** (900 mg, 2.61 mmol) in THF (25 ml) were added ethylchloroformate (340 mg, 3.13 mmol) and DIPEA (505 mg, 3.91 mmol). The mixture was stirred at room temperature for 5 hours. Methanol (2ml) was added and then NaBH₄ (600 mg, 15.86 mmol) in small portions at 0°C. Stirring was continued at 0°C for a further 1 h. Diethyl ether (15ml) was added and the
20 product was extracted with diethyl ether. The ether phase was dried over MgSO₄.

Purification by flash chromatography (SiO₂, toluene: ethyl acetate) gave the title compound (230 mg, 44%).


¹H NMR (400 MHz) δ 8.61 (s, 1H), 7.27-7.22 (m, 4H), 7.36-7.30 (m, 4H), 4.81 (s, 2H), 4.60-4.10 (br, 1H).

¹³C NMR (100 MHz) δ 153.28, 150.23, 150.15, 140.45, 136.64, 136.62, 135.46, 135.33, 131.23, 129.27, 128.94, 63.16.

MS *m/z* 331, 333, 335 (M+H)⁺

10 Examples of the Invention

Example 1




[5,6-bis(4-chlorophenyl)pyrazin-2-yl]methanol, **Inte. E** (230 mg, 0.69 mmol) was dissolved in DCM (3ml) and mixed with water (2ml). NaOH (0.53 mg, 13.25 mmol) and tetrabutylammonium hydrogen sulphate (18 mg, 0.05 mmol) were added at room temperature. 4-Fluorobenzyl bromide (145 mg, 0.77 mmol) was added and the mixture stirred for 4 hours at room temperature. Diethyl ether (10ml) was added and the product was extracted with water and dried (MgSO₄) to yield the product (285 mg, 93%).

¹H NMR (399.964 MHz) δ 8.78 (s, 1H), 7.41-7.35 (m, 6H), 7.31-7.27 (m, 4H), 7.09-7.01 (m, 2H), 4.79 (s, 2H), 4.69 (s, 2H).

EXAMPLE 2

2,3-BIS(4-CHLOROPHENYL)-5-[(PIPERIDINE-1-YLOXY)CARBONYL]PYRAZINE



To a solution of 5,6-bis(4-chlorophenyl)pyrazine-2-carbonyl chloride, **Inte. D** (84 mg, 0.23 mmol) in DCM (1ml) was added slowly at room temperature a solution of hydroxypiperidine (93 mg, 0.91mmol) in pyridine (5 ml). After 40 minutes at rt, the solvent was removed in vacuo and the residue redissolved in diethyl ether. Extracted with 1M HCl (aq) and K₂CO₃ (aq) and dried (MgSO₄). The solvent was removed in vacuo to yield the subtitle compound (58 mg, 59%).

¹H NMR (399.964 MHz) δ 9.19 (s, 1H), 7.47-7.26 (m, 8H), 3.71-3.50 (m, 2H), 3.16-2.74 (m, 2H), 1.98-1.77 (m, 4H), 1.77-1.57 (m, 1H), 1.40-1.23 (m, 1H).

¹³C NMR (100.58 MHz) δ 162.59, 154.17, 151.20, 143.18, 140.79, 136.22, 136.17, 136.09, 135.89, 131.42, 131.29, 129.08, 129.04, 57.87, 25.30, 23.27.

MS *m/z* 428, 430, 432 (M+H)⁺.

Pharmacological Activity

Compounds of the present invention are active against the receptor product of the CB1 gene. The affinity of the compounds of the invention for central cannabinoid receptors is demonstrable in methods described in Devane et al, Molecular Pharmacology, 1988, 34,605 or those described in WO01/70700 or EP 656354. Alternatively the assay may be performed as follows.

10μg of membranes prepared from cells stably transfected with the CB1 gene were suspended in 200μl of 100mM NaCl, 5mM MgCl₂, 1mM EDTA, 50mM HEPES (pH 7.4), 1mM DTT, 0.1% BSA and 100μM GDP. To this was added an EC80 concentration of agonist (CP55940), the required concentration of test compound and 0.1μCi [³⁵S]-GTPγS. The reaction was allowed to proceed at 30°C for 45 min. Samples were then transferred on to GF/B filters using a cell harvester and washed with wash buffer (50mM Tris (pH 7.4),

5mM MgCl₂, 50mM NaCl). Filters were then covered with scintilant and counted for the amount of [³⁵S]-GTPγS retained by the filter.


Activity is measured in the absence of all ligands (minimum activity) or in the presence of an EC80 concentration of CP55940 (maximum activity). These activities are set as 0% and 100% activity respectively. At various concentrations of novel ligand, activity is calculated as a percentage of the maximum activity and plotted. The data are fitted using the equation $y=A+((B-A)/(1+((C/x)^D)))$ and the IC₅₀ value determined as the concentration required to give half maximal inhibition of GTPγS binding under the conditions used.

10

The compounds of the present invention are active at the CB1 receptor (IC₅₀ <1 micromolar). Most preferred compounds have IC₅₀ <200 nanomolar.

Claims

1. A compound of formula (I)



wherein R^1 and R^2 independently represent phenyl, thienyl or pyridyl each of which is
 5 independently optionally substituted by one or more groups represented by Z;

Z represents a C_{1-8} alkyl group, a C_{1-6} alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, mono or di C_{1-3} alkylamido, C_{1-3} alkylsulphonyl, C_{1-3} alkylsulphonyloxy, C_{1-3} alkoxycarbonyl, carboxy,
 10 cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl, acetyl, an aromatic heterocyclic group, optionally substituted by halo, alkyl, trifluoromethyl or trifluoromethoxy and a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups,
 15 hydroxy, fluoro, benzyl or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl;

R^3 represents a group of formula $(CH_2)_nCOOR^7$

in which n is 0, 1, 2, 3 or 4 and

20 R^7 represents a C_{4-12} alkyl group, a C_{3-12} cycloalkyl group or a $(C_{3-12}$ cycloalkyl) C_{1-3} alkyl-group each of which is optionally substituted by one or more of the following: a C_{1-6} alkyl group; fluoro, amino or hydroxy, or

R^7 represents a group $-(CH_2)_a$ phenyl in which a is 0, 1, 2, 3 or 4 and the phenyl group is
 25 optionally substituted by one or more groups represented by Z which may be the same or different or

R^7 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of the of the following : oxygen, sulphur or nitrogen; wherein the heterocyclic group is optionally substituted by one or more C_{1-3} alkyl groups, C_{1-3} acyl groups, hydroxy, amino or benzyl; or

R^3 represents a group of formula $-(CH_2)_o-O-(CH_2)_p-R^8$ in which o and p independently represent an integer 0, 1, 2, 3 or 4 and R^8 represents a C_{1-12} alkyl group optionally substituted by one or more of the following: a C_{1-6} alkyl group; fluoro, hydroxy, or or an amino group $-NR^xR^y$ in which R^x and R^y independently represent H or C_{1-4} alkyl ;

or R^8 represents phenyl optionally independently substituted by one or more Z groups or R^8 represents an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one following : oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different ;

R^3 represents a group of formula $-(CH_2)_qR^9$ in which q is 0, 1, 2, 3 or 4 and R^9 represents a C_{3-12} cycloalkyl group, phenyl, an aromatic heterocyclic group or a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more of one following : oxygen, sulphur or nitrogen wherein each of these rings is optionally substituted by one or more groups represented by Z which may be the same or different ; or

R^4 represents a group of formula $-(CH_2)_m-O-(CO)-R^{10}$ in which m represents an integer 0, 1, 2, 3 or 4 , and in which R^{10} represents a C_{1-12} alkyl group optionally substituted by one or more fluoro, hydroxy, or amino or R^{10} represents a group of formula $-(CH_2)_qR^9$ in which q and R^9 are as previously described.

and pharmaceutically acceptable salts thereof.

2. A compound selected from one or more of the following:

2,3-bis(4-chlorophenyl)-5-[[[4-fluorobenzyl]oxy]methyl] pyrazine
5 2,3-BIS(4-CHLOROPHENYL)-5-[(PIPERIDINE-1-YLOXY)CARBONYL]PYRAZINE

and pharmaceutically acceptable salts thereof.

3. A compound of formula I as claimed in any previous claim for use as a medicament.

4. A pharmaceutical formulation comprising a compound of formula I, as defined in any
either claim 1 or claim 2 and a pharmaceutically acceptable adjuvant, diluent or carrier.

5. Use of a compound of formula I according to claim 1 in the preparation of a
15 medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as
psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive
disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive
disorders, anorexia, bulimia, attention disorders, epilepsy, and related conditions, and
neurological disorders such as dementia, neurological disorders, Parkinson's Disease,
20 Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and
endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal
systems, and extended abuse, addiction and/or relapse indications.

6. A method of treating obesity, psychiatric disorders, psychotic disorders, schizophrenia
25 and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders,
memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders,
epilepsy, and related conditions, neurological disorders, neurological disorders ,
Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune,
cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the
30 respiratory and gastrointestinal system, and extended abuse, addiction and/or relapse

indications, comprising administering a pharmacologically effective amount of a compound of formula I according to claim 1 to a patient in need thereof.

7. A compound as defined in either claim 1 or claim 2 for use in the treatment of obesity.

5

ABSTRACT

The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.